Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hormone Refractory Prostate Cancer: New Studies In Austria

29.03.2010
- Three clinical trials started at the Medical University of Vienna
- Commissioned by multinational pharmaceutical firms

The Medical University of Vienna has been commissioned by international pharmaceutical firms to conduct three clinical trials of the treatment of recurrent prostate tumors (hormone refractory prostate carcinomas). The new approaches comprise immunotherapy, hormone therapy and an augmented form of the current standard treatment with docetaxel.

Team leader Prof. Dr. Michael Krainer and his colleagues will concentrate primarily on tumors diagnosed late or those which recur after surgical interventions, and which do not (or no longer) respond to common treatments such as androgen deprivation.

IMMUNOTHERAPY
The team will investigate the use of the monoclonal antibody ipilimumab as part of the immunotherapeutic treatment. This antibody can cause the body's own immune system to react against cancer cells. Prof. Krainer said that "the use of ipilimumab rather than docetaxel has led to rather surprising successes during the past year in a small-scale trial. In three patients, a tumor that had been hard to treat became so small that it could be surgically removed. Since a small-scale trial of this nature only allows limited claims to be made about the drug, ipilimumab is now being investigated further in a larger study."
HORMONE THERAPY
A hormone treatment based on the drug MDV3100 is also being trialed by the team at the Medical University of Vienna. This is used as a second-line treatment after the initial treatment with docetaxel. MDV3100 is a substance that blocks the androgen receptor and thus offers a new approach to the prevention of hormone dependent tumor growth.
AUGMENTED STANDARD TREATMENT
In the past, Prof. Krainer and his team were able to show the efficacy of docetaxel versus other common chemotherapeutic drugs. The third trial at the Medical University of Vienna will test the combination of docetaxel with the tyrosine kinase inhibitor sunitinib. As part of the trial, the researchers will examine biomarkers in the patients' blood that will yield information about the progress of the treatment.
TOP QUALITY RESEARCH IN AUSTRIA
"We are delighted that multinational pharmaceutical companies find in Austria the optimal environment and competent partners for clinical trials and basic research", said Dr. René Siegl, Managing Director of the Austrian investment promotion company ABA - Invest in Austria. "This shows that the conditions at the location Austria are ideal". More than 15 percent of Austrian R&D expenditure comes from foreign commissions. With 2.73 percent of the GNP in 2009 being spent on research, Austria has closed the gap with other European countries at the forefront of innovation. The aim is a research quota of 4 percent by 2020. In future Austria will create even greater incentives for businesses to attract innovation centers and will further develop collaborative endeavors between the scientific and business worlds.

For further information please contact:

Hanni Grassauer
ABA - Invest in Austria
Opernring 3
1010 Wien, Austria
T +43 / 1 / 588 58 57
F +43 / 1 / 586 86 59
E h.grassauer@aba.gv.at
Mag. Marta Korinkova
PR-Assistentin & Office Managerin
PR&D - Public Relations für Forschung & Bildung
T +43 1 505 70 44
F +43 1 505 50 83
E korinkova@prd.at
Campus Vienna Biocenter 2
1030 Vienna, Austria

Marta Korinkova | PR&D
Further information:
http://www.investinaustria.at
http://www.prd.at

More articles from Life Sciences:

nachricht Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover

nachricht First transcription atlas of all wheat genes expands prospects for research and cultivation
17.08.2018 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>